REGENXBIO Inc. Stock News

Announcing initial data from its Phase I/II trial for RGX-111 in severe Mucopolysaccharidosis Type I (MPS I), REGENXBIO (RGNX) suggested there was systemic and CNS biomarker…

Regenxbio Inc RGNX announced additional interim data from Cohorts 1-3 of Phase 1/2 trial of RGX-121 for patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II),  Get the I

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on…

ROCKVILLE, Md., Feb. 8, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday,

Regenxbio Inc (RGNX) shares closed 0.7% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 17.6% year-to-date, down 44.7% over the past 12 months, and up 43.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 50.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3151.1% The company's stock price performance over the past 12 months lags the peer average by 179.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

RGNX announced promising safety and efficacy data from its SCS micro injector trial.

REGENXBIO Inc. (NASDAQ:RGNX)s share price gapped up prior to trading on Monday . The stock had previously closed at $30.47, but opened at $32.13. REGENXBIO shares last traded at $31.71, with a volume of 13 shares. A number of brokerages recently commented on RGNX. Roth Capital raised their target price on REGENXBIO from $15.00 to []

Wall Street brokerages predict that REGENXBIO Inc. (NASDAQ:RGNX) will post earnings per share (EPS) of $6.14 for the current quarter, according to Zacks. Two analysts have provided estimates for REGENXBIOs earnings. The lowest EPS estimate is $1.78 and the highest is $9.39. REGENXBIO reported earnings of ($1.24) per share in the same quarter last year, []

Brokerages expect REGENXBIO Inc. (NASDAQ:RGNX) to post $443.53 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for REGENXBIO’s earnings. The highest sales estimate is $495.60 million and the lowest is $391.45 million. REGENXBIO reported sales of $21.45 million during the same quarter last year, which would […]

Different market evaluation and appropriate data techniques are often used to compile and evaluate the data which is offered in this Hypercholesterolemia Treatment market report. In addition, we have an in-house information prediction model that forecasts product demand until 2027.

Everence Capital Management Inc. acquired a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,140 shares of the biotechnology companys stock, valued at approximately $215,000. Several other hedge funds and other []

BioCardia (NASDAQ:BCDA) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability. Analyst Ratings This is a breakdown of recent ratings for BioCardia and REGENXBIO, as provided by MarketBeat. []

Louisiana State Employees Retirement System increased its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 15.3% in the third quarter, Holdings Channel.com reports. The institutional investor owned 18,100 shares of the biotechnology companys stock after acquiring an additional 2,400 shares during the period. Louisiana State Employees Retirement Systems holdings in REGENXBIO were worth $759,000 at the end []